Enfortumab Vedotin in Advanced Urothelial Carcinoma

Yeon, Sang Hoon

doi:10.1056/nejmc2106975

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of advanced urothelial cancer, as locally pT2, pT3a, pT4 muscle invasive urothelial carcinoma or urothelial carcinoma with metastatic disease, with all its complexities, will certainly become the focus of considerable attention in the immediate future, in part due to new investments in health and social care (such as the Europe’s Beating Cancer Plan, the National Cancer Plan, and the National Recovery and Resilience Plan, a reform and investment package to help Italy recover from the COVID-19 pandemic), and to the imminent arrival on the market of innovative treatment solutions ( 3 , 4 ). While these treatments promise to improve the survival and quality of life of patients with advanced urothelial cancer, they will also require a new decision-making mindset on the part of clinicians and healthcare administrators at various levels.…”

Section: Introductionmentioning

confidence: 99%

U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario

Bracarda,

Iacovelli,

Baldazzi

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionAdvanced urothelial carcinoma remains aggressive and very hard to cure, while new treatments will pose a challenge for clinicians and healthcare funding policymakers alike. The U-CHANGE Project aimed to redesign the current model of care for advanced urothelial carcinoma patients to identify limitations (“as is” scenario) and recommend future actions (“to be” scenario).MethodsTwenty-three subject-matter experts, divided into three groups, analyzed the two scenarios as part of a multidimensional consensus process, developing statements for specific domains of the disease, and a simplified Delphi methodology was used to establish consensus among the experts.ResultsRecommended actions included increasing awareness of the disease, increased training of healthcare professionals, improvement of screening strategies and care pathways, increased support for patients and caregivers and relevant recommendations from molecular tumor boards when comprehensive genomic profiling has to be provided for appropriate patient selection to ad hoc targeted therapies.DiscussionWhile the innovative new targeted agents have the potential to significantly alter the clinical approach to this highly aggressive disease, the U-CHANGE Project experience shows that the use of these new agents will require a radical shift in the entire model of care, implementing sustainable changes which anticipate the benefits of future treatments, capable of targeting the right patient with the right agent at different stages of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario

Bracarda,

Iacovelli,

Baldazzi

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Precision medicine for urothelial carcinoma: An international perspective

Fontes,

de Almeida,

Cárcano

et al. 2024

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

Fontes¹,

Almeida²,

Cavalin³

et al. 2022

OTT

View full text Add to dashboard Cite

Urothelial carcinoma is the second most frequent genitourinary malignancy. Despite the poor prognosis, new treatment options have emerged and have expanded the therapeutic landscape for the disease. Although major improvements have been achieved, many patients experience rapid disease progression and low responses in subsequent lines of therapy. Sacituzumab govitecan is an ADC that targets Trop-2, which is highly expressed in urothelial cancers. Promising results in early clinical trials have led to further drug development which confirmed encouraging efficacy. Sacituzumab govitecan has been given accelerated approval in 2021 for patients with locally advanced and metastatic urothelial cancer who previously received a platinum containing chemotherapy and either a programmed death receptor-1 or programmed death ligand inhibitor. The results are promising, with encouraging efficacy and safety, however responses are not universal. There is a growing comprehension of mechanisms of resistance and predictive biomarkers that are crucial to improving outcomes. In this review, we summarize the current knowledge on antibody-drug conjugates and the clinical findings that led to the approval of Sacituzumab govitecan and discuss the therapeutic potential of new combinations, mechanisms of resistance and predictive biomarkers.

show abstract

Enfortumab Vedotin in Advanced Urothelial Carcinoma

Cited by 3 publications

References 6 publications

U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario

U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario

Precision medicine for urothelial carcinoma: An international perspective

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

Contact Info

Product

Resources

About